BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

...commercial development for Type I diabetes is TOL-3021, a vaccine in Phase IIa testing from Tolerion Inc....
...celiac disease Companies and Institutions Mentioned ImmunoMolecular Therapeutics LLC, Broomfield, Colo. JDRF, New York, N.Y. Tolerion Inc....
BioCentury | Dec 1, 2016
Targets & Mechanisms

Not a peripheral story

...tolerogenic mixture of islet antigen peptides, in a Phase I study in Type I diabetes. Tolerion Inc....
...New Brunswick, N.J. King’s College London, London, U.K. Opexa Therapeutics Inc. (NASDAQ:OPXA), The Woodlands, Texas Tolerion Inc....
BioCentury | Jul 29, 2013
Product Development

Tolerion's second wind

...Armed with positive Phase IIa data in Type I diabetes, Tolerion Inc. is now seeking funding for...
...go at developing a selective immunomodulatory approach that previously failed in multiple sclerosis. In 2011, Tolerion...
...a co-founder of both Tolerion and Bayhill, said the study is proof of principle for Tolerion's...
BioCentury | Jul 1, 2013
Clinical News

TOL-3021: Phase II data

...3 or 6 mg TOL-3021 for 12 weeks. Data were published in Science Translational Medicine. Tolerion...
...younger Type I diabetics when administered before large numbers of beta calls have been destroyed. Tolerion...
...from Stanford University, which had previously licensed the product to the now-defunct Bayhill Therapeutics Inc. Tolerion Inc....
BioCentury | Jun 27, 2013
Clinical News

Tolerion reports Phase II data for Type I diabetes vaccine

...or 6 mg TOL-3021 for 12 weeks. Data were published in Science Translational Medicine . Tolerion...
...younger Type I diabetics when administered before large numbers of beta cells have been destroyed. Tolerion...
BioCentury | Dec 9, 2002
Finance

Ebb & Flow

...fund, which came from individual investors. The firm's portfolio so far includes autoimmune drug developer Tolerion...
Items per page:
1 - 6 of 6
BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

...commercial development for Type I diabetes is TOL-3021, a vaccine in Phase IIa testing from Tolerion Inc....
...celiac disease Companies and Institutions Mentioned ImmunoMolecular Therapeutics LLC, Broomfield, Colo. JDRF, New York, N.Y. Tolerion Inc....
BioCentury | Dec 1, 2016
Targets & Mechanisms

Not a peripheral story

...tolerogenic mixture of islet antigen peptides, in a Phase I study in Type I diabetes. Tolerion Inc....
...New Brunswick, N.J. King’s College London, London, U.K. Opexa Therapeutics Inc. (NASDAQ:OPXA), The Woodlands, Texas Tolerion Inc....
BioCentury | Jul 29, 2013
Product Development

Tolerion's second wind

...Armed with positive Phase IIa data in Type I diabetes, Tolerion Inc. is now seeking funding for...
...go at developing a selective immunomodulatory approach that previously failed in multiple sclerosis. In 2011, Tolerion...
...a co-founder of both Tolerion and Bayhill, said the study is proof of principle for Tolerion's...
BioCentury | Jul 1, 2013
Clinical News

TOL-3021: Phase II data

...3 or 6 mg TOL-3021 for 12 weeks. Data were published in Science Translational Medicine. Tolerion...
...younger Type I diabetics when administered before large numbers of beta calls have been destroyed. Tolerion...
...from Stanford University, which had previously licensed the product to the now-defunct Bayhill Therapeutics Inc. Tolerion Inc....
BioCentury | Jun 27, 2013
Clinical News

Tolerion reports Phase II data for Type I diabetes vaccine

...or 6 mg TOL-3021 for 12 weeks. Data were published in Science Translational Medicine . Tolerion...
...younger Type I diabetics when administered before large numbers of beta cells have been destroyed. Tolerion...
BioCentury | Dec 9, 2002
Finance

Ebb & Flow

...fund, which came from individual investors. The firm's portfolio so far includes autoimmune drug developer Tolerion...
Items per page:
1 - 6 of 6